Evan Osmundson, MD, PhD
Dr. Evan Osmundson is a radiation oncologist specializing in lung cancer, mesothelioma, and thoracic cancers at Vanderbilt University Medical Center in Nashville, Tennessee. He is highly skilled in the use of innovative radiation treatments, including, 3D conformal radiation, adaptive radiotherapy, Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiotherapy, Stereotactic Radiosurgery, Total Body Radiation, and Total Skin Radiation.[1]
Dr. Osmundson is also the Medical Director of the Department of Radiation Oncology, and in that role, he is dedicated to improving patients’ experience and the efficiency of care delivery as they make their way from diagnosis, to treatment, to recovery.
Education and Career
Dr. Osmundson graduated with honors from the Medical Scientist Training Program at the University of Illinois College of Medicine, where he earned both his M.D. and his Ph.D. degrees. He then completed an internship and residency at Ascension Illinois/St. Joseph Hospital in Chicago, and an additional residency in Radiation Oncology at Stanford University.[1] His efforts have resulted in him having co-authored 30 peer-reviewed articles and participating in four clinical trials over the past 15 years. Those trials include:[2]
SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy – A Phase I/II Study.
- Enrollment Status: Recruiting
- Publish Date: October 17, 2023
- Intervention Type: Drug, Biological, Other, Procedure, Radiation
- Study Phase: Phase 1/Phase 2
Vertebral Bone Marrow in Lung Cancer Attention Trial (VMAT)
- Enrollment Status: Recruiting
- Publish Date: October 05, 2023
- Intervention Type: Other
- Study Phase: Not Applicable
(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)
- Enrollment Status: Not yet recruiting
- Publish Date: October 31, 2023
- Intervention Type: Drug, Radiation, Procedure, Biological
- Study Phase: Phase 1/Phase 2
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
- Enrollment Status: Terminated
- Publish Date: March 06, 2023
- Intervention Type: Drug, Radiation
- Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
- Study Phase: Phase 2
Dr. Osmundson’s recent publications include:
- Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy? De Vis, J., Cmelak, A., Osmundson, E.>; Journal of Clinical Oncology. 2023 Dec 1.
- Accuracy and Reliability of Chatbot Responses to Physician Questions. Rachel S Goodman, J Randall Patrinely, Cosby A Stone Jr, Eli Zimmerman, Rebecca R Donald, Sam S Chang, Sean T Berkowitz, Avni P Finn, Eiman Jahangir, Elizabeth A Scovi…>; JAMA Network Open. 2023 Oct 2
- Assessing the Accuracy and Reliability of AI-Generated Medical Responses: An Evaluation of the Chat-GPT Model. Douglas Johnson, Rachel Goodman, J Patrinely, Cosby Stone, Eli Zimmerman, Rebecca Donald, Sam Chang, Sean Berkowitz, Avni Finn, Eiman Jahangir, Elizabeth Scoville, Tyl…>; Research Square. 2023 Feb 28
